| Full Name | Edward Clay |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1901 63rd St, Kenosha, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841696044 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 13857-40 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Edward Clay, 1901 63rd St, Kenosha, WI 53143-4467 Ph: (262) 653-1202 | Edward Clay, 1901 63rd St, Kenosha, WI 53143-4467 Ph: (262) 653-1202 |
News Archive
For many newborn babies, an enzyme that breaks down the molecule bilirubin doesn't activate right away. The resulting bilirubin buildup can lead to jaundice, a typically harmless condition that causes a baby's skin to temporarily appear yellow.
The University of Montreal Hospital Research Centre is launching a major international clinical trial to test a minimally invasive and safer surgical approach for patients with lung cancer: video-assisted thoracoscopic (VATS) lobectomy with ultrasonic pulmonary artery sealing.
In studies with monkeys, researchers have identified in detail the brain regions responsible for the unique ability of primates, including humans, to process visual 3D shapes to guide their sophisticated manipulation of objects.
Gene expression in breast cancer provides valuable biological information for better determining the diagnosis, treatment, risk of relapse and survival rate. However, the most common form of characterizing breast cancer is by histopathological techniques. This study, headed by Dr Aleix Prat, Head of the Translational Genomics Group at the Vall d'Hebron Institute of Oncology (VHIO) and an oncologist at the Breast Cancer Unit of the Vall d´Hebron University Hospital, focused on hormone-sensitive breast tumours known as luminals.
Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread.
› Verified 4 days ago
Mitchell Robak, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2207 80th St, Kenosha, WI 53143 Phone: 262-658-3731 | |
Carolyn Schiller, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3820 52nd St, Kenosha, WI 53144 Phone: 262-652-9665 Fax: 262-652-0896 | |
Daniel Lupi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3805 80th St, Kenosha, WI 53142 Phone: 262-694-0750 | |
Dr. Danielle T Kroll, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9916 75th St Ste 103, Kenosha, WI 53142 Phone: 262-925-0201 Fax: 262-925-8373 | |
Daisy Nichols, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7701 Green Bay Rd, Kenosha, WI 53142 Phone: 262-612-1610 | |
Aaron Buresh, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3710 57th Ave, Kenosha, WI 53144 Phone: 262-652-1474 | |
Lisa Mutchler, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7525 Sheridan Rd, Kenosha, WI 53143 Phone: 262-652-2396 |